98%
921
2 minutes
20
A biocompatible topical thermo-reversible hydrogel containing Pranoprofen (PF)-loaded nanostructured lipid carriers (NLCs) was studied as an innovative strategy for the topical treatment of skin inflammatory diseases. The PF-NLCs-F127 hydrogel was characterized physiochemically and short-time stability tests were carried out over 60 days. In vitro release and ex vivo human skin permeation studies were carried out in Franz diffusion cells. In addition, a cytotoxicity assay was studied using the HaCat cell line and in vivo tolerance study was performed in humans by evaluating the biomechanical properties. The anti-inflammatory effect of the PF-NLCs-F127 was evaluated in adult male Sprague Daw-ley rats using a model of inflammation induced by the topical application of xylol for 1 h. The developed PF-NLCs-F127 exhibited a heterogeneous structure with spherical PF-NLCs in the hydrogel. Furthermore, a thermo-reversible behaviour was determined with a gelling temperature of 32.5 °C, being close to human cutaneous temperature and thus favouring the retention of PF. Furthermore, in the ex vivo study, the amount of PF retained and detected in human skin was high and no systemic effects were observed. The hydrogel was found to be non-cytotoxic, showing cell viability of around 95%. The PF-NLCs-F127 is shown to be well tolerated and no signs of irritancy or alterations of the skin's biophysical properties were detected. The topical application of PF-NLCs-F127 hydrogel was shown to be efficient in an inflammatory animal model, preventing the loss of stratum corneum and reducing the presence of leukocyte infiltration. The results from this study confirm that the developed hydrogel is a suitable drug delivery carrier for the transdermal delivery of PF, improving its dermal retention, opening the possibility of using it as a promising candidate and safer alternative to topical treatment for local skin inflammation and indicating that it could be useful in the clinical environment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778151 | PMC |
http://dx.doi.org/10.3390/ph15010022 | DOI Listing |
Adv Pharm Bull
July 2025
Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal- 576104, India.
Purpose: The present study aimed to fabricate microneedles (MNs) for transdermal delivery of insulin. Chitosan-conjugated carboxy phenyl boronic acid polymer was synthesized and characterized to load insulin in the form of nanoparticles.
Methods: Optimized insulin nanoparticles (ILN-NPs) were loaded into MN arrays by micromolding, and the resulting MN patches were characterized by scanning electron microscopy (SEM) and mechanical failure tests.
Mater Today Bio
October 2025
Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Zhejiang Chinese Medical University, 75 Jinxiu Road, Wenzhou, 325000, China.
Transdermal drug delivery systems (TDDS) represent a non-invasive approach to achieve controlled drug release through the skin barrier, offering stable plasma concentrations while avoiding gastrointestinal and hepatic metabolism. However, the skin barrier poses physical challenges, making it difficult for most drugs to penetrate deep tissues using TDDS. This review systematically summarizes the research progress in nanocarrier design, physical technology application, and artificial intelligence (AI)-driven TDDS optimization design aimed at overcoming the key problem of skin barrier penetration.
View Article and Find Full Text PDFInt J Biol Macromol
September 2025
Department of Dermatology, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China. Electronic address:
Skin aging serves as a critical indicator of systemic health decline. Despite Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) being a key therapeutic target, mechanistic understanding remains incomplete and potent, safe activators are lacking, hindering clinical progress. This study proposes the "Barrier-Skin-Systemic Aging Axis," demonstrating that epidermal barrier disruption accelerates aging via PPARγ suppression.
View Article and Find Full Text PDFInt J Pharm
September 2025
Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Guangzhou Road 300, Nanjing, People's Republic of China; Engineering Research Center of Intelligent Theranostics Technology and Instruments, Ministry of Education, People's Republic of China. Electronic address:
Background: Ultrasound-assisted transdermal drug delivery, or sonophoresis, enhances skin permeability, offering a non-invasive alternative for drug administration. However, its clinical application remains limited because of an insufficient understanding of its underlying mechanisms and optimal parameters. This study investigates the factors influencing ultrasound-enhanced drug absorption and examines its biological effects on skin structures and HaCaT cells, providing a comprehensive analysis of its mechanisms.
View Article and Find Full Text PDFSleep Med Clin
September 2025
Parkinson Foundation Centre of Excellence, King's College Hospital and King's College, London, United Kingdom; King's College Hospital, London, Dubai, UAE; Institute of Psychiatry, Psychology and Neuroscience, King's College, Dementech Clinical Neuroscience Centre London, United Kingdom. Electronic
Sleep dysfunction can affect almost 90% of Parkinson's disease (PD) patients and insomnia related to fragmented sleep is common. Satisfactory management remains an unmet need although dopaminergic non-oral treatments utilising a continuous drug delivery strategy appears to help sleep maintenance insomnia. Transdermal therapy with rotigotine or subcutaneous apomorphine infusion is effective while recent data show considerable efficacy of intrajejunal or subcutaneous levodopa infusion on alleviation of insomnia in PD.
View Article and Find Full Text PDF